Inhibition of adhesion molecule expression in early progression of atherosclerosis in dyslipidemia model on sprague dawley rats by darapladib

Background and Objective: Dyslipidemia has been established as major risk factor contribute to atherosclerosis. One of emerging theory contribute to atherosclerosis is involvement of lipoprotein-associated phospholipase A2 (Lp-PLA2). Darapladib as inhibitor Lp-PLA2 have pro and contra about it is effect in atherosclerosis inhibition. This study aimed to examine the effects of darapladib on Lp-PLA2, intracellular adhesion molecule-1(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression in aortic tissue in vivo. Materials and Methods: This was a true experimental laboratory, in vivo post test only control group design, with 24 Rattus novergicus Sprague Dawley strain rats were divided into six groups based on two serial time (normal group 8 weeks, dyslipidemic group 8 weeks, dyslipidemic group treated with darapladib 20 mg/200 g b.wt., 8 weeks and normal group 16 weeks, dyslipidemic group 16 weeks, dyslipidemic group treated with darapladib 20 mg/200 g b.wt., 16 weeks). The parameters of this study were Lp-PLA2, ICAM-1 and VCAM-1 measured by immunofluorescence and observed with a confocal laser scanning microscope in aortic smooth muscle cell. One way analysis of variance test and Pearson’s correlation coefficient showed Darapladib had a significant effect (p<0.05) in decreasing Lp-PLA2, ICAM-1 and VCAM-1 expression in aortic tissue of hypercholesterol diet given Sprague Dawley rat. Results: Darapladib 20 mg/200 g b.wt., is proven to decrease Lp-PLA2, ICAM-1 and VCAM-1 expression in aortic tissue in vivo. Conclusion: These finding provides a comprehensive mechanism inhibition of early progression of atherosclerotic process through inhibition of adhesion molecules by darapladib.